Joe Chang, MD, PhD, MS, FASTRO

Dr. Chang holds a Texas 4000 Distinguished Professorship at MD Anderson Cancer Center. He is honored as a Fellow of the American Society of Radiation Oncology (ASTRO) and a Fellow of the American College of Radiology (ACR). He has received the Best Doctors of America award. He is a Board Director of the International Association for the Study of Lung Cancer, and the Clinical Scientific Program Chair for the Particle Therapy Cooperative Group.

As a pioneer in the fields of stereotactic ablative radiotherapy (SABR), proton therapy, and immunotherapy for lung cancer, Dr. Chang has published more than 330 peer-reviewed articles in prestigious journals, including The Lancet, Nature, JAMA, Journal of Clinical Oncology, Journal of Thoracic Oncology, and International Journal of Radiation Oncology Biology Physics (Red Journal), among others. His randomized trials comparing SABR alone versus SABR plus immunotherapy (I-SABR) in early-stage lung cancer (Lancet 2023), surgery versus SABR in operable Stage I lung cancer (Lancet Oncology 2015 and 2021), stereotactic proton versus photon radiotherapy in challenging early-stage lung cancer (Red J 2018) are the first and only ones published worldwide. He piloted cutting-edge proton therapy technology for locally advanced lung cancer and led phase II clinical study of concurrent proton therapy and chemotherapy in Stage III lung cancer (JAMA Oncology 2017), the implementation of intensity-modulated proton therapy (IMPT) in lung cancer (Red J 2014). His research has been instrumental in establishing the role of SABR, proton therapy, and combined immunotherapy with SABR (I-SABR) in both early-stage and advanced lung cancer.

Disclosures:

• Employment: MD Anderson Cancer Center:Professor:Employee
• Compensation: IBA: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Compensation Payment-End Date: ongoing ;BMS: Research Grants, Research Funding, Research Salary Support,Grant Research Funding-End Date: 06/01/2025 ;AstraZeneca: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Honoraria-End Date: 09/30/2024 ;Siemans: Research Grants, Research Funding, Research Salary Support,Grant Research Funding-End Date: 07/01/2025 ;AstraZeneca: Research Grants, Research Funding, Research S
• Ownership: none
• Leadership: PTCOG:Co-chair for Scientific Program Committee;IASLC:Board Director;NCCN:Panel